Remote Ischemic Preconditioning in a Cirrhotic Patient Undergoing Major Hepatectomy

Emrullah Birgin¹, Christoph Reissfelder¹, Nuh Rahbari¹

¹. Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, DEU

Corresponding author: Emrullah Birgin, emrullah.birgin@umm.de

Abstract

Remote ischemic preconditioning (RIPC) has been shown to reduce ischemic reperfusion injury for patients undergoing hepatectomy for colorectal liver metastasis. We present a case of a 69-year-old male who underwent right hepatectomy for a multifocal hepatocellular carcinoma of the right liver and concomitant liver cirrhosis (Child-Pugh stage A). We performed portal vein embolization prior to surgery and intraoperative RIPC of the iliac vessels. The postoperative course after major hepatectomy went uneventful.

Categories: Gastroenterology, General Surgery, Oncology

Keywords: cirrhosis, liver failure, hepatoprotection, hepatectomy

Introduction

Remote ischemic preconditioning (RIPC) is characterized by short episodes of ischemia and reperfusion induced by temporary arterial occlusion of a limb to release cytokines, which mediate protection from ischemic injury in a distant organ of interest (e.g. heart, bowel, or liver) [1,2]. In a randomized trial, RIPC was demonstrated to provide hepatoprotection in patients undergoing hepatectomy for colorectal liver metastasis [3]. However, the hepatoprotective effects of RIPC remain unknown for patients undergoing major hepatectomy in the context of significant cirrhosis. Herein, we report a case of hepatocellular carcinoma (HCC) with underlying liver cirrhosis and intraoperative RIPC of the iliac vessels.

Case Presentation

A 69-year-old man with alcohol-related liver cirrhosis (Child-Pugh stage A) was referred to our hospital due to an incidental finding of two hepatic masses. Alpha fetoprotein and serology for hepatitis B and C were negative. On MRI, a 3.5 x 3 cm mass was seen in liver segment V at the bifurcation of the right portal pedicle and another 1.5 x 1 cm mass in liver segment VII (Figure 1).

Received 06/26/2020
Review began 07/02/2020
Review ended 07/03/2020
Published 07/07/2020

© Copyright 2020

Birgin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

FIGURE 1: Preoperative imaging

Preoperative MRI was performed a week prior to hepatectomy and shows a considerable degree of hypertrophy of the left liver lobe following portal vein embolization. The MRI demonstrates the hepatic lesions in segment V (indicated by the white star, A), and in segment VII (indicated by the white short arrow, B). The white long arrow in 1A indicates micro-spheres in the right portal vein with adherent thrombotic material (indicated by three white triangles).

A core needle biopsy of the lesion in segment V confirmed the diagnosis of a moderately differentiated (G2) HCC (Ki67: 20%). At the multidisciplinary board, a right hepatectomy was recommended. Liver volumetry revealed a total liver volume of 1,511 ml and a volume of the future liver remnant of 386 ml (future liver remnant ratio: 25%). The patient's baseline liver biochemical tests showed normal findings (Table 1).

How to cite this article

Birgin E, Reissfelder C, Rahbari N (July 07, 2020) Remote Ischemic Preconditioning in a Cirrhotic Patient Undergoing Major Hepatectomy. Cureus 12(7): e9056. DOI 10.7759/cureus.9056

Parameters	Result	Reference range
Albumin (g/l)	39.1	34-50
Bilirubin (mg/dl)	0.86	0.2-1.0
Creatinine (mg/dl)	0.92	0.81-1.44
Alkaline phosphatase (U/l)	64	40-130
Gamma-glutamyl transferase (U/l)	62	0-60
Aspartate aminotransferase (U/l)	44	0-50
Alanine aminotransferase (U/l)	32	0-50
White blood count (x10 ⁹ /l)	5.17	4.2-10.2
Hemoglobin (g/dl)	15.0	13.2-16.7
Platelets (x10 ⁹ /l)	147	145-348
International normalized ratio (INR)	1.11	0.9-1.15
Quick (%)	80	70-130
C-reactive protein (mg/l)	<2.9	0-5

TABLE 1: Preoperative laboratory tests

Due to the small future liver remnant, the presence of cirrhosis, and the need for a major hepatectomy, preoperative right portal vein embolization (PVE) was performed using 500-700 μ m embosphere microspheres. The intervention was uneventful. On the day after the intervention, his total serum bilirubin increased to 2 mg/dl and his transaminases around 100 U/l (Figure 2).

FIGURE 2: Blood parameters over time

ALT, alanine aminotransferase; AST, aspartate aminotransferase; AP, alkaline phosphatase; gGT, gamma-glutamyl transferase; bilirubin; INR, international normalized ratio; platelets.

PVE, portal vein embolization; post-PVE, day after portal vein embolization; preop, day before surgery; POD, postoperative day.

A follow-up MRI at four weeks post-PVE demonstrated significant hypertrophy of the future liver remnant with a volume of 638 ml and a total liver volume of 1,706 ml (future liver remnant ratio: 37%). However, there was suspicion of microspheres and adhering thrombus protruding into the main portal vein trunk

(Figure 1).

For this reason, intraoperative exploration of the portal vein trunk was planned. As prolonged hepatic ischemia was anticipated in the case of vascular reconstruction of the portal vein, the decision was made to apply RIPC.

The patient was taken to the operating room five weeks after right PVE. After induction of anesthesia and before laparotomy, three cycles of ischemia and reperfusion (three 10-minute inflations and deflations) were induced via a tourniquet on the patients' right thigh that was intermittently inflated to a pressure of 100 mmHg above the baseline systolic blood pressure of the patient. Remarkably, the patient responded to the episodes of reperfusion with a transient drop of his blood pressure (mean relative drop of systolic blood pressure of 13% and mean relative drop of diastolic blood pressure of 8%), indicating the effectiveness of the intervention [3]. No complications were noted due to the application of RIPC. All three portal vein vessels were clamped with vascular clamps and a venotomy of the main portal vein trunk was carried out (Figure 3).

FIGURE 3: Hepatectomy

(A) Around the left hepatic pedicle a vessel sling was placed. After clamping the portal vein both proximally and distally, the thrombosis was removed through venotomy of the right portal vein. The thrombotic material is demonstrated at the tip of the forceps. (B) Resected specimen.

The thrombus was found to be adherent to the main portal vein wall. After it was peeled off the portal vein wall, the main portal vein was closed resulting in takedown of the right portal vein. The cumulative duration of portal vein occlusion was 25 minutes. Subsequently, the right hepatic artery was suture ligated. The liver parenchymal transection was performed using an energy device and intermittent portal triad clamping (PTC) for a cumulative duration of 30 minutes. The right hepatic pedicle was mass transected and the resection completed with takedown of the right hepatic vein using a stapling device. No drains were placed and the abdomen was closed in a regular fashion. The total operating time was 281 minutes, and the total amount of intraoperative blood loss was 500 ml.

After the surgery, the patient was monitored on an intermediate care unit for 24 hours before he was transferred to the regular ward. The entire postoperative course was uneventful. Remarkably, serial analyses of his biochemical liver tests demonstrated no impairment of his postoperative liver function. Of particular interest, there was only a mild increase in his transaminase levels, bilirubin level, platelets, and international normalized ratio (INR) as markers of hepatic parenchymal injury (Figure 2). Peak values of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were already observed 24 hours postoperatively; however, these values almost normalized over time (Figure 2). The patient was discharged on postoperative day 8. At one-, three-, and six-month follow-up, the patient had a normal liver function and there were no signs of recurrence.

Discussion

Surgical resection remains the primary curative therapy for patients with HCC [4]. However, up to 40% of patients with HCC present with concomitant portal vein thrombosis at the time of diagnosis and are rarely considered as candidates for surgical resection or even for further treatment [5]. Furthermore, a significant percentage of patients with HCC suffer from liver cirrhosis of varying severity. Cirrhotic patients undergoing hepatic resection are at high risk of postoperative morbidity and in particular posthepatectomy liver failure (PHLF) [6]. In fact, major hepatectomy is not feasible in many cirrhotic patients with HCC due to their liver's low functional reserve. Intraoperative hemorrhage is known to further increase the risk of PHLF in cirrhotic patients undergoing major hepatectomy [7,8]. PTC might be an effective measure to reduce the amount of intraoperative blood loss. However, there is substantial evidence that the cirrhotic liver is more susceptible to ischemia reperfusion injury (IRI) that might put patients at risk for inadequate postoperative liver regeneration and PHLF [9]. This is of particular importance in patients requiring complex resections with or

without vascular reconstruction. Commonly applied methods to minimize IRI include intermittent PTC and ischemic preconditioning with a brief period of hepatic inflow occlusion and reperfusion followed by a prolonged period of PTC [10]. Recently, the concept of RIPC has gained increasing attention in the literature. RIPC was initially introduced in 1993 in a rodent cardiac surgery model and since numerous preclinical studies proved a protective effect for RIPC against IRI in various organ systems of mammals, including the liver, heart, brain, and intestine [11-13]. Although the benefit of RIPC to reduce myocardial injury after cardiac surgery was also shown in various clinical trials, two large randomized controlled trials failed to show an improved clinical outcome [14-17]. A recent randomized controlled feasibility study demonstrated RIPC as a valuable method to reduce liver injury in patients undergoing hepatectomy for colorectal liver metastasis without steatosis or fibrosis [3]. Kanoria et al. induced RIPC by a pneumatic tourniquet around the upper thigh for 60 minutes (three 10-minute inflations and deflations). Twenty-four hours after hepatectomy, the mean serum transaminase levels were almost 50% lower in patients with the preconditional stimulus compared to patients without preconditioning [3]. Nevertheless, another recent trial failed to show a statistically significant decrease of serum transaminase levels 24 hours after hepatectomy in patients with HCC and RIPC compared to sham treatment [18]. But none of these patients underwent PVE or had concomitant portal vein thrombosis before surgery. Furthermore, the trial used a different RIPC protocol with a pneumatic tourniquet around the upper arm for 20 minutes (four 5-minute inflations and deflations) and the majority of the included patients underwent only minor hepatectomies. Thus, one has to consider those different methods of RIPC were applied in all these trials (e.g. duration of vascular occlusion, the total number of cycles, direct vascular clamping vs limb tourniquet) prohibiting a direct comparison and conclusion of these studies.

In our case report, we observed similar transaminase levels 24 hours after major hepatectomy in a patient with Child-A liver cirrhosis demonstrating RIPC to be feasible and effective in a pre-damaged liver with portal vein thrombosis. Although the underlying mechanisms of RIPC are not fully understood, RIPC was identified to induce systematic serotonin release of platelets which induces endothelial stimulation of vascular endothelial growth factor (VEGF) [19]. Nevertheless, the molecular mechanisms of RIPC in underlying fibrosis or cirrhosis are unclear. Of note, one has to consider that primary liver tumors are also able to produce VEGF, potentially, interfering with VEGF-dependent effects by RIPC [20].

Conclusions

To the best of our knowledge, this is the first report of RIPC in a patient with HCC and concomitant portal vein thrombosis. The uneventful postoperative course after major hepatectomy suggested that RIPC was beneficial even after PVE and intraoperative portal vein reconstruction. RIPC reflects a promising method in patients with impaired liver function. As multimodal therapeutic approaches in HCC are emerging, RIPC seems to be another new modality to provide safe hepatic resections. However, further prospective trials are required to evaluate the definitive role of RIPC in patients undergoing major hepatectomy.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Jung KW, Kang J, Kwon HM, Moon YJ, Jun IG, Song JG, Hwang GS: Effect of remote ischemic preconditioning conducted in living liver donors on postoperative liver function in donors and recipients following liver transplantation: a randomized clinical trial. *Ann Surg.* 2020, 271:646-653. [10.1097/SLA.0000000000003498](https://doi.org/10.1097/SLA.0000000000003498)
2. Roubille F, Macia JC, Ivanov F, et al.: Effects of remote ischemic conditioning on kidney injury in at-risk patients undergoing elective coronary angiography (PREPARE study): a multicenter, randomized clinical trial. *Sci Rep.* 2019, 9:11985. [10.1038/s41598-019-47106-7](https://doi.org/10.1038/s41598-019-47106-7)
3. Kanoria S, Robertson FP, Mehta NN, Fusai G, Sharma D, Davidson BR: Effect of remote ischaemic preconditioning on liver injury in patients undergoing major hepatectomy for colorectal liver metastasis: a pilot randomised controlled feasibility trial. *World J Surg.* 2017, 41:1322-1330. [10.1007/s00268-016-3823-4](https://doi.org/10.1007/s00268-016-3823-4)
4. Forner A, Reig M, Bruix J: Hepatocellular carcinoma. *Lancet.* 2018, 391:1301-1314. [10.1016/S0140-6736\(18\)30010-2](https://doi.org/10.1016/S0140-6736(18)30010-2)
5. Minagawa M, Makuuchi M: Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. *World J Gastroenterol.* 2006, 12:7561-7567. [10.3748/wjg.v12.i47.7561](https://doi.org/10.3748/wjg.v12.i47.7561)
6. Rahbari NN, Garden OJ, Padbury R, et al.: Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). *Surgery.* 2011, 149:713-724. [10.1016/j.surg.2010.10.001](https://doi.org/10.1016/j.surg.2010.10.001)
7. Nishio T, Taura K, Koyama Y, et al.: Prediction of posthepatectomy liver failure based on liver stiffness measurement in patients with hepatocellular carcinoma. *Surgery.* 2016, 159:399-408.

- [10.1016/j.surg.2015.06.024](https://doi.org/10.1016/j.surg.2015.06.024)
8. Birgin E, Tesfazgi W, Knoth M, Wilhelm TJ, Post S, Rückert F: Evaluation of the new ISGLS definitions of typical posthepatectomy complications. *Scand J Surg*. 2019, 108:130-136. [10.1177/1457496918798202](https://doi.org/10.1177/1457496918798202)
 9. Veteläinen R, van Vliet AK, van Gulik TM: Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy. *Ann Surg*. 2007, 245:44-50. [10.1097/01.sla.0000225253.84501.0e](https://doi.org/10.1097/01.sla.0000225253.84501.0e)
 10. Eipel C, Glanemann M, Nuessler AK, Menger MD, Neuhaus P, Vollmar B: Ischemic preconditioning impairs liver regeneration in extended reduced-size livers. *Ann Surg*. 2005, 241:477-484. [10.1097/01.sla.0000154264.41201.51](https://doi.org/10.1097/01.sla.0000154264.41201.51)
 11. Kambakamba P, Linecker M, Schneider M, et al.: Novel benefits of remote ischemic preconditioning through VEGF-dependent protection from resection-induced liver failure in the mouse. *Ann Surg*. 2018, 268:885-893.
 12. Zhao Y, Xue Y, Liu Z, et al.: Role of the Janus kinase 2/signal transducers and activators of transcription 3 pathway in the protective effect of remote ischemia preconditioning against cerebral ischemia-reperfusion injury in rats. *Neuroreport*. 2019, 30:664-670. [10.1097/WNR.0000000000001257](https://doi.org/10.1097/WNR.0000000000001257)
 13. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P: Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. *Circulation*. 1993, 87:893-899. [10.1161/01.cir.87.3.893](https://doi.org/10.1161/01.cir.87.3.893)
 14. Hausenloy DJ, Mwamure PK, Venugopal V, et al.: Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. *Lancet*. 2007, 370:575-579. [10.1016/s0140-6736\(07\)61296-3](https://doi.org/10.1016/s0140-6736(07)61296-3)
 15. Candilio L, Malik A, Ariti C, et al.: Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial. *Heart*. 2015, 101:185-192. [10.1136/heartjnl-2014-306178](https://doi.org/10.1136/heartjnl-2014-306178)
 16. Meybohm P, Bein B, Brosteanu O, et al.: A multicenter trial of remote ischemic preconditioning for heart surgery. *N Engl J Med*. 2015, 373:1397-1407. [10.1056/NEJMoa1413579](https://doi.org/10.1056/NEJMoa1413579)
 17. Hausenloy DJ, Candilio L, Evans R, et al.: Remote ischemic preconditioning and outcomes of cardiac surgery. *N Engl J Med*. 2015, 373:1408-1417. [10.1056/NEJMoa1413534](https://doi.org/10.1056/NEJMoa1413534)
 18. Teo JY, Ho AFW, Bulluck H, et al.: Effect of remote ischemic preconditioning on liver injury in patients undergoing liver resection: the ERIC-LIVER trial [Epub ahead of print]. *HPB*. 2020, [10.1016/j.hpb.2019.12.002](https://doi.org/10.1016/j.hpb.2019.12.002)
 19. Oberkofler CE, Limani P, Jang JH, et al.: Systemic protection through remote ischemic preconditioning is spread by platelet-dependent signaling in mice. *Hepatology*. 2014, 60:1409-1417. [10.1002/hep.27089](https://doi.org/10.1002/hep.27089)
 20. Zhang Z, Zhang F, Lu Y, Zheng S: Update on implications and mechanisms of angiogenesis in liver fibrosis. *Hepatol Res*. 2015, 45:162-178. [10.1111/hepr.12415](https://doi.org/10.1111/hepr.12415)